XTL Biopharmaceuticals Ltd.
XTLB
$1.27
$0.043.25%
| Weiss Ratings | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.52 | |||
| Price History | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 15.45% | |||
| 30-Day Total Return | -9.93% | |||
| 60-Day Total Return | -35.53% | |||
| 90-Day Total Return | -30.60% | |||
| Year to Date Total Return | -35.53% | |||
| 1-Year Total Return | -59.16% | |||
| 2-Year Total Return | 0.79% | |||
| 3-Year Total Return | -45.02% | |||
| 5-Year Total Return | 37.89% | |||
| 52-Week High % Change | -64.45% | |||
| 52-Week Low % Change | 12.69% | |||
| Price | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $3.46 | |||
| 52-Week Low Price | $1.09 | |||
| 52-Week Low Price (Date) | Mar 27, 2025 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 10.96M | |||
| Enterprise Value | 9.23M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | 0.00 | |||
| Earnings Per Share Growth | 44.00% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 300.00 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.27 | |||
| Enterprise Value/EBITDA (TTM) | -12.08 | |||
| Enterprise Value/EBIT | -12.06 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 544.91M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 972 3 611 6600 | |||
| Address | -- | |||
| Website | www.xtlbio.com | |||
| Country | Israel | |||
| Year Founded | 1993 | |||
| Profitability | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -14.46% | |||
| Return on Equity | -- | |||
| Income Statement | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -764.20K | |||
| EBIT (TTM) | -765.00K | |||
| Net Income (TTM) | -1.78M | |||
| Net Income Avl. to Common (TTM) | -1.78M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 62.03% | |||
| EPS Diluted (TTM) | 0.00 | |||
| EPS Diluted Growth (Q YOY) | 57.14% | |||
| Balance Sheet | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.01M | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 2.05M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.22M | |||
| Current Ratio (Q) | 9.932 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 2.43M | |||
| Total Current Liabilities (Q) | 206.00K | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 206.00K | |||
| Total Common Equity (Q) | 2.22M | |||
| Cash Flow | XTLB - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -- | |||
| Levered Free Cash Flow (TTM) | -- | |||
| Cash from Operations (TTM) | -- | |||
